Chemical Nameapremilast
Dosage FormTablet (oral; 10 mg, 20 mg, 30 mg)
Drug ClassInhibitors
SystemSkin, Immune, Musculoskeletal
CompanyAmgen Inc.
Approval Year2014


  • For the treatment of adult patients with active psoriatic arthritis.
  • For the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Otezla (apremilast) Prescribing Information 2014Celgene Corporation, Summit, NJ
Document TitleYearSource
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. 2020The Cochrane Database of Systematic Reviews
Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis.2020Orphanet Journal of Rare Diseases
Comparability of European league against rheumatology recommended Pharmacological treatments of Oral Ulcers associated with Behçet’s Disease: A systematic literature review of randomized controlled trials.2020Open Access Rheumatology: Research and Reviews
Biologics and small molecules in patients with scalp psoriasis: a systematic review. 2020Journal of Dermatological Treatment
Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis. 2019Seminars in Arthritis and Rheumatism
Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.2019Rheumatology International
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.2019Journal of the European Academy of Dermatology and Venereology
Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.2018Future Medicine
Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.2018Journal of the American Academy of Dermatology
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.2018Journal of Dermatological Treatment
Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.2018PLoS One
Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.2018Rheumatology International
Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.2016RMD Open
Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.2016Seminars in Arthritis and Rheumatism